Michael Hislop

1.7k total citations
15 papers, 1.3k citations indexed

About

Michael Hislop is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Michael Hislop has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 10 papers in Virology and 2 papers in Emergency Medicine. Recurrent topics in Michael Hislop's work include HIV/AIDS drug development and treatment (13 papers), HIV/AIDS Research and Interventions (12 papers) and HIV Research and Treatment (10 papers). Michael Hislop is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), HIV/AIDS Research and Interventions (12 papers) and HIV Research and Treatment (10 papers). Michael Hislop collaborates with scholars based in South Africa, United States and Israel. Michael Hislop's co-authors include Gary Maartens, Leon Regensberg, Jean B. Nachega, David W. Dowdy, Richard E. Chaisson, Hoàng Dũng Nguyễn, Mark F. Cotton, Melanie Lo, Saad B. Omer and Rory Leisegang and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and PLoS Medicine.

In The Last Decade

Michael Hislop

15 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Hislop South Africa 11 1.2k 514 333 309 212 15 1.3k
Leon Regensberg South Africa 9 1.2k 1.0× 494 1.0× 337 1.0× 304 1.0× 176 0.8× 15 1.2k
Kenneth Tapia United States 23 857 0.7× 478 0.9× 235 0.7× 495 1.6× 141 0.7× 57 1.3k
Tsitsi Apollo Zimbabwe 19 841 0.7× 221 0.4× 453 1.4× 343 1.1× 64 0.3× 56 975
Karl‐Günter Technau South Africa 24 1.4k 1.2× 673 1.3× 396 1.2× 471 1.5× 305 1.4× 80 1.6k
Tafireyi Marukutira United States 12 621 0.5× 135 0.3× 314 0.9× 256 0.8× 93 0.4× 33 737
Nafuna Wamai Uganda 10 1.0k 0.9× 203 0.4× 539 1.6× 509 1.6× 146 0.7× 10 1.1k
Shannon Hader United States 19 949 0.8× 260 0.5× 334 1.0× 670 2.2× 115 0.5× 33 1.1k
Richard Conviser United States 13 805 0.7× 171 0.3× 269 0.8× 564 1.8× 172 0.8× 31 949
Margaret Mclees United States 3 1.3k 1.1× 390 0.8× 399 1.2× 1.1k 3.4× 157 0.7× 6 1.5k
Patrick Ryscavage United States 10 609 0.5× 252 0.5× 243 0.7× 171 0.6× 116 0.5× 26 697

Countries citing papers authored by Michael Hislop

Since Specialization
Citations

This map shows the geographic impact of Michael Hislop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Hislop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Hislop more than expected).

Fields of papers citing papers by Michael Hislop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Hislop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Hislop. The network helps show where Michael Hislop may publish in the future.

Co-authorship network of co-authors of Michael Hislop

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Hislop. A scholar is included among the top collaborators of Michael Hislop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Hislop. Michael Hislop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cohen, Karen, Annemie Stewart, André Pascal Kengne, et al.. (2018). A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 80(3). 325–329. 6 indexed citations
2.
Karamchand, Sumanth, Rory Leisegang, Michael Schomaker, et al.. (2016). Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. Medicine. 95(9). e2844–e2844. 45 indexed citations
3.
Meintjes, Graeme, et al.. (2015). Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Research and Therapy. 12(1). 39–39. 21 indexed citations
4.
5.
Leisegang, Rory, Gary Maartens, Michael Hislop, Leon Regensberg, & Susan Cleary. (2010). Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. BMC Health Services Research. 10(S1). S3–S3. 11 indexed citations
6.
Nachega, Jean B., Rory Leisegang, David Bishai, et al.. (2010). Association of Antiretroviral Therapy Adherence and Health Care Costs. Annals of Internal Medicine. 152(1). 18–25. 58 indexed citations
7.
Nachega, Jean B., Michael Hislop, Hoàng Dũng Nguyễn, et al.. (2009). Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(1). 65–71. 346 indexed citations
8.
Leisegang, Rory, Susan Cleary, Michael Hislop, et al.. (2009). Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis. PLoS Medicine. 6(12). e1000189–e1000189. 45 indexed citations
9.
Nachega, Jean B., Michael Hislop, David W. Dowdy, et al.. (2008). Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 22(16). 2117–2125. 62 indexed citations
10.
Nachega, Jean B., Michael Hislop, David W. Dowdy, et al.. (2008). Efavirenz versus nevirapine-based initial treatment of HIV infection: Clinical and virological outcomes in Southern African adults (AIDS (2008) 22, 16, (2117-2126)). 22(17). 1 indexed citations
11.
Bisson, Gregory P., Robert Gross, Scarlett L. Bellamy, et al.. (2008). Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy. PLoS Medicine. 5(5). e109–e109. 131 indexed citations
12.
Sinanovic, Edina, et al.. (2007). HIV and AIDS, STI and TB in the private sector : health care delivery. South African Health Review. 2007(1). 201–211. 4 indexed citations
13.
Nachega, Jean B., Michael Hislop, David W. Dowdy, et al.. (2007). Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes. Annals of Internal Medicine. 146(8). 564–573. 301 indexed citations
14.
Nachega, Jean B., Michael Hislop, David W. Dowdy, et al.. (2006). Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(1). 78–84. 227 indexed citations
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leon Regensberg Breakdown of academic impact, for papers by Kenneth Tapia Breakdown of academic impact, for papers by Tsitsi Apollo Breakdown of academic impact, for papers by Karl‐Günter Technau Breakdown of academic impact, for papers by Tafireyi Marukutira Breakdown of academic impact, for papers by Nafuna Wamai Breakdown of academic impact, for papers by Shannon Hader Breakdown of academic impact, for papers by Richard Conviser Breakdown of academic impact, for papers by Margaret Mclees Breakdown of academic impact, for papers by Patrick Ryscavage
Rankless by CCL
2026